Status:
COMPLETED
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
Lead Sponsor:
Allergan
Conditions:
Overactive Bladder
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A in treating overactive bladder in spinal cord injury or multiple sclerosis patients.
Eligibility Criteria
Inclusion
- Urinary incontinence as a result of neurogenic overactive bladder due to spinal cord injury or multiple sclerosis
- Inadequate response to anticholinergic medication used to treat overactive bladder
Exclusion
- History of evidence of pelvic or urologic abnormality
- Previous or current diagnosis of bladder or prostate cancer
- Urinary tract infection at time of enrollment
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2010
Estimated Enrollment :
416 Patients enrolled
Trial Details
Trial ID
NCT00311376
Start Date
August 1 2006
End Date
May 1 2010
Last Update
December 4 2015
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Oak, Michigan, United States
2
Randwick, New South Wales, Australia
3
Innsbruck, Austria
4
Ghent, Belgium